<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of Ewing sarcoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of Ewing sarcoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of Ewing sarcoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark C Gebhardt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven G DuBois, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alberto S Pappo, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Maki, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raphael E Pollock, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ewing sarcoma (ES) is a rare malignancy that most often presents as an undifferentiated primary bone tumor; less commonly, it arises in soft tissue (extraosseous ES). Advances in multidisciplinary management have markedly improved long-term survival. (See  <a class="medical medical_review" href="/d/html/7744.html" rel="external">"Clinical presentation, staging, and prognostic factors of Ewing sarcoma", section on 'Prognostic factors'</a>.)</p><p>This topic will discuss the management of ES. The pathology and molecular genetics; the clinical presentation, diagnosis, and prognosis; and radiation therapy for ES are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7742.html" rel="external">"Epidemiology, pathology, and molecular genetics of Ewing sarcoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7744.html" rel="external">"Clinical presentation, staging, and prognostic factors of Ewing sarcoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7748.html" rel="external">"Radiation therapy for Ewing sarcoma family of tumors"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">GENERAL TREATMENT PRINCIPLES</span><span class="headingEndMark"> — </span>Despite the fact that fewer than 25 percent of patients have overt metastases at the time of diagnosis, ES is considered a systemic disease. Because of the high relapse rate (80 to 90 percent) in patients undergoing local therapy alone, it is surmised that the majority of patients have subclinical metastatic disease at the time of diagnosis, even in the absence of overt metastases.</p><p>Chemotherapy can successfully eradicate these deposits, and modern treatment plans all include chemotherapy, usually administered prior to and following local treatment. For patients with localized disease, the addition of intensive multiagent chemotherapy to local therapy has had a dramatic impact on survival, and reported five-year survival rates are now approximately 70 percent [<a href="#rid1">1-10</a>].</p><p>A subset of patients with advanced disease may be cured by multimodality therapy, although the long-term survival rates are clearly lower than for patients with localized disease [<a href="#rid11">11</a>]. Approaching a patient who has metastatic ES with noncurative intent is rarely, if ever, appropriate since it is not possible to predict a priori which patients will be cured. Because of these issues, clinicians experienced in the treatment of ES must direct the surgery and radiation therapy (RT), and coordination with the medical/pediatric oncologist is essential [<a href="#rid5">5,12,13</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Adult patients</span><span class="headingEndMark"> — </span>Treatment of adults with ES should generally be guided by the same general principles as those used for younger individuals. However, few clinical trials address treatment in adults since most studies have excluded older individuals.</p><p>Less than 5 percent of cases of ES arise in adults over the age of 40. Some studies have defined "older" patients as those over the age of 15 at initial diagnosis, while others have used a cutpoint of 18 years. Although some studies suggest that older age is an adverse prognostic factor in ES, it is not clear if the worse prognosis in older individuals is due to biological differences or differences in treatment regimens (ie, regimens used in pediatric versus those used in adult medical oncology). </p><p>In general, adults who are treated with contemporary adjuvant and neoadjuvant chemotherapy for localized ES may do as well as children [<a href="#rid14">14-16</a>]. Observational studies also suggest that survival rates for adults with ES are similar to those of children [<a href="#rid14">14,16-24</a>]. As an example, one retrospective series of 102 adult patients ≥18 years of age treated between 1977 and 2005 showed an overall survival (OS) of 69 percent and an event-free survival (EFS) of 52 percent [<a href="#rid22">22</a>]. A subsequent cohort (treated between 1993 and 2007) had better outcomes (five-year OS and EFS of 73 and 60 percent, respectively). This cohort routinely had the addition of <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, similar to pediatric treatment protocols.</p><p class="headingAnchor" id="H4"><span class="h1">TREATMENT FOR LOCALIZED DISEASE</span></p><p class="headingAnchor" id="H5"><span class="h2">Neoadjuvant chemotherapy</span><span class="headingEndMark"> — </span>Most modern treatment plans utilize initial (neoadjuvant or induction) chemotherapy followed by local treatment and additional chemotherapy. Reduction of local tumor volume is accomplished in the majority of patients, and this can facilitate resection. This is particularly important with regard to limb-sparing procedures for extremity lesions, but it may also be important for rib, chest wall, and vertebral primaries [<a href="#rid25">25-27</a>]. Initially, chemotherapy was used in the adjuvant setting to control metastatic disease, but it is now administered prior to local therapy (neoadjuvant therapy) to treat micrometastatic disease earlier and to improve local control [<a href="#rid28">28</a>]. Since most treatment failures are attributable to systemic metastatic disease, local therapy considerations should be planned to avoid complications that might compromise the administration of effective systemic therapy. (See  <a class="medical medical_review" href="/d/html/7739.html" rel="external">"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management"</a>.)</p><p>Although patients with extraosseous ES (EES) have been treated in the past on protocols for rhabdomyosarcoma and have a similar response to multimodality therapy [<a href="#rid7">7</a>], EES responds to the same chemotherapy regimens as osseous ES and patients with these tumors should be treated similarly [<a href="#rid29">29-32</a>]. Data suggest that patients with EES have slightly superior outcomes compared with patients with osseous ES [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H2761249158"><span class="h3">Selection of therapy</span><span class="headingEndMark"> — </span>For patients with localized ES, we recommend initial chemotherapy with alternating cycles of <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>/<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>/<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>/<a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (VDC/IE) rather than vincristine, ifosfamide, doxorubicin, and etoposide (VIDE). The VDC/IE regimen improved overall survival (OS) in a randomized trial, and is shorter in duration with less toxicity [<a href="#rid34">34</a>]. </p><p>Different chemotherapy regimens have been used internationally for the treatment of localized ES. The VDC/IE regimen, which is used in the United States, was developed based on data from the Intergroup Ewing sarcoma studies (IESS-I, IESS-II, and IESS-III) [<a href="#rid3">3,35,36</a>]. The VIDE regimen used in Europe was based on data from the (Euro-EWING) 99/EWING 2008 trial [<a href="#rid37">37</a>]. (See <a class="local">'Other strategies'</a> below.)</p><p>The superiority of VDC/IE over VIDE was established in an open-label phase III trial (EE2012) conducted in Europe. In this study, 640 patients with ES were randomly assigned to initial treatment with VDC/IE administered on an interval-compressed schedule (every two weeks with hematopoietic growth factor support) or the <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (VIDE) regimen [<a href="#rid34">34</a>]. At median follow-up of 47 months, VDC/IE improved EFS and OS compared with VIDE (three-year EFS 67 versus 61 percent, HR 0.71, 95% CI 0.55-0.92; three-year OS 82 versus 74 percent; HR 0.62, 95% CI 0.46-0.85). While grade ≥3 toxicity rates were similar between the two treatment arms (90 versus 91 percent), the risk of grade ≥3 febrile neutropenia was lower for VDC/IE compared with VIDE (58 versus 74 percent). The duration of therapy for VDC/IE was also shorter by approximately two months. </p><p>However, combining interval-compressed VDC/IE with chemotherapy effective in relapsed disease (eg, <a class="drug drug_general" data-topicid="10007" href="/d/drug information/10007.html" rel="external">topotecan</a>/<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>) does not appear to confer additional clinical benefit. In a separate randomized phase III COG trial (AEWS1031) conducted in 629 patients with localized treatment-naïve ES, the addition of <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>/topotecan/cyclophosphamide to the interval-compressed VDC/IE regimen did not improve EFS or OS [<a href="#rid38">38,39</a>]. </p><p class="headingAnchor" id="H997380609"><span class="h3">Interval-compressed VDC/IE</span><span class="headingEndMark"> — </span>For patients age &lt;18 years with localized ES, we recommend interval-compressed therapy with alternating cycles of <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>/<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>/<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (VDC) and <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>/<a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (VDC/IE) given every two weeks with hematopoietic growth factor support  (<a class="graphic graphic_table graphicRef110260" href="/d/graphic/110260.html" rel="external">table 1</a>), rather than every three weeks without growth factor support. In a phase III trial (AEWS0031), this approach improved event-free survival (EFS) and OS in this population without increased toxicity or higher risk of second (subsequent) malignant neoplasms [<a href="#rid40">40,41</a>]. </p><p>For patients age ≥18 years, we offer VDC/IE either every two weeks with hematopoietic growth factor support or every three weeks without growth factor support. A subgroup analysis of this population in AEWS0031, which mainly enrolled younger patients, did not demonstrate a difference in EFS between the two treatment arms.</p><p>For patients receiving interval-compressed VDC/IE, we typically administer four to six cycles of chemotherapy followed by local therapy in the absence of disease progression. We then administer additional cycles of the same chemotherapy in the postoperative setting, for a total of 14 to 17 cycles. Clinical evidence that chemotherapy is effectively treating the tumor include relief of tumor-related pain, decrease in tumor size, fall in lactate dehydrogenase (LDH) level, radiologic improvement, and evidence of necrosis in the resected specimen.</p><p>Treatment for localized ES can be intensified with interval compression, in which chemotherapy cycles are administered every 14 days instead of every 21 days [<a href="#rid42">42</a>]. A randomized phase III trial (AEWS0031) from the Children's Oncology Group (COG) conducted in North America established interval-compressed therapy with alternating cycles of VDC/IE as the preferred initial chemotherapy regimen for children with localized ES  (<a class="graphic graphic_table graphicRef110260" href="/d/graphic/110260.html" rel="external">table 1</a>) [<a href="#rid40">40,41</a>]. In this study, 587 patients with localized ES were randomly assigned to receive 14 alternating cycles of VDC/IE every 21 or 14 days. A majority of patients enrolled (88 percent) were age &lt;18 years. In preliminary results available in abstract form, interval-compressed VDC/IE given every 14 days improved ten-year EFS (70 versus 61 percent) and ten-year OS (76 versus 69 percent) compared with VDC/IE given at 21-day intervals [<a href="#rid41">41</a>]. In subgroup analyses, compared with chemotherapy every three weeks, interval compressed VDC/IE also improved ten-year EFS in patients with pelvic primary tumors (67 versus 43 percent), large tumor volume ≥200 mL (74 versus 46 percent), those with the presence of viable tumor at the time of surgery (75 versus 47 percent), and those age &lt;18 (73 versus 64 percent, HR 0.71, 95% CI 0.52-0.99). However, among patients age ≥18 years, the study did not demonstrate a difference in ten-year EFS for interval-compressed therapy over every three-week therapy (53 versus 37 percent, HR 0.75, 95% CI 0.38-1.47).</p><p>The toxicity of both regimens was similar [<a href="#rid40">40</a>]. There was also no difference in the ten-year cumulative incidence of second (subsequent) malignant neoplasms between treatment every 14 days (3.2 percent) and treatment every 21 days (4.2 percent). </p><p class="headingAnchor" id="H339360192"><span class="h3">Other strategies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-dose chemotherapy with hematopoietic cell transplantation</strong> – The role of consolidative high-dose chemotherapy with autologous hematopoietic cell transplantation is uncertain. This approach improved outcomes for children with high-risk localized disease who were treated with the VIDE induction regimen [<a href="#rid37">37</a>]. However, high-dose chemotherapy with autologous hematopoietic cell transplantation has not been used with interval-compressed VDC/IE chemotherapy because the efficacy and toxicities of such an approach have not been addressed in prior trials [<a href="#rid43">43</a>]. Additionally, in a phase III trial (EE2012), interval-compressed VDC/IE improved OS over VIDE among the subgroup of patients with high-risk localized disease (tumor volume ≥200 mL at diagnosis) [<a href="#rid34">34</a>]. (See <a class="local">'Interval-compressed VDC/IE'</a> above.)</p><p></p><p class="bulletIndent1">The role of consolidative high-dose chemotherapy followed by autologous hematopoietic cell transplantation for localized high-risk disease was evaluated in the European Ewing Tumour Working Initiative of National Groups (Euro-EWING) 99/EWING 2008 trial. High-risk disease was defined as a poor histologic response after receiving six cycles of VIDE (76 percent of the cohort) or tumor volume at diagnosis ≥200 mL if unresected, initially resected, or resected after radiation therapy (RT) [<a href="#rid37">37</a>] In this study, 240 patients with high-risk localized ES were treated with six courses of VIDE plus one course of consolidation <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9318" href="/d/drug information/9318.html" rel="external">dactinomycin</a>, and <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> (VAI). Patients were then randomly assigned to either one course of <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a> plus <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a> followed by autologous hematopoietic cell rescue or seven courses of standard chemotherapy with VAI. At a median follow-up of 7.8 years, high-dose chemotherapy followed by hematopoietic cell transplantation improved both EFS (eight-year EFS 61 versus 47 percent) and OS (eight-year OS 65 versus 56 percent). </p><p></p><p class="bulletIndent1">Severe acute toxicities were more common in the high-dose chemotherapy group, and three patients died in this group, two of treatment-related toxicity; the third patient did not receive dose-intense chemotherapy or high-dose chemotherapy because of renal dysfunction. The risk of secondary malignancies in long-term survivors was not reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose escalation of VDC/IE</strong> – We do not use a dose-escalated VDC/IE as initial chemotherapy of ES. In a randomized phase III clinical trial conducted by the COG, dose escalation of VDC/IE without hematopoietic cell support did not improve outcomes in patients with newly diagnosed localized disease [<a href="#rid43">43</a>]. Furthermore, concerns for an increased risk of secondary malignancies in patients receiving dose-intense therapy have tempered enthusiasm for this approach.</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Local treatment</span><span class="headingEndMark"> — </span>Following initial systemic therapy, local control for ES can be achieved by surgery, RT, or both. The choice between RT and surgery is based on patient characteristics, the potential harm and benefit of the treatment options, and patient preference. In most cases of extremity ES of bone, limb-salvage resections and reconstructions similar to those used for osteosarcomas have been used most frequently if it is anticipated that a wide margin can be achieved. (See  <a class="medical medical_review" href="/d/html/7739.html" rel="external">"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management"</a>.)</p><p class="headingAnchor" id="H2421829082"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>Patients who might lose function from surgical procedures because of tumor location (such as the periacetabular region of the pelvis) or extent may be offered RT as an alternative. However, advances in endoprosthetic reconstruction such as 3D printed, custom prostheses even for the periacetabular area have become available to reconstruct surgical defects [<a href="#rid44">44-46</a>]. Data are limited for the long-term outcomes of these prosthetic reconstructive procedures. One observational study of 35 patients with pelvic ES suggested that preoperative radiotherapy and surgical resection was associated with better histologic response and OS than either surgery alone or in combination with postoperative radiation [<a href="#rid47">47</a>]. The functional outcomes were better with hip transposition (ie, no implant used in the reconstruction) than if an implant were used, likely due to a much lower incidence of infection in those patients without an implant. However, this study is limited by the small number of patients.</p><p>Surgery is preferred for potentially resectable lesions and for those arising in dispensable bones (eg, fibula, rib, small lesions of the hands or feet) for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>It avoids the risk of secondary radiation-associated sarcomas. (See  <a class="medical medical_review" href="/d/html/7748.html" rel="external">"Radiation therapy for Ewing sarcoma family of tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of the degree of necrosis in the excised tumor can permit refinements in the estimate of prognosis. (See  <a class="medical medical_review" href="/d/html/7739.html" rel="external">"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the skeletally immature child, resection may be associated with less morbidity than RT, which can retard bone growth and cause deformity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Technical advances in the endoprostheses used for limb reconstruction of other bone sarcomas have led to improved long-term outcomes and can be applied to patients with ES as well. (See  <a class="medical medical_review" href="/d/html/7739.html" rel="external">"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management", section on 'Reconstruction techniques'</a>.)</p><p></p><p>Although there are no randomized trials comparing surgery with RT for local control, multiple retrospective series and a systematic review suggest superior local control and, in some cases, EFS for surgery compared with RT alone [<a href="#rid13">13,48-51</a>]. However, selection bias accounts for at least some of these results (ie, smaller, more favorably situated peripheral tumors or those that respond well to chemotherapy are more likely to be resected, while larger, axial lesions are radiated). The difference in local control between RT and surgery has been abrogated in some series when age and primary tumor site were controlled for [<a href="#rid52">52-54</a>]. Radiation dose and proper field planning are also important factors in local control. The role of RT in the local management of ES is discussed separately. (See  <a class="medical medical_review" href="/d/html/7748.html" rel="external">"Radiation therapy for Ewing sarcoma family of tumors"</a>.)</p><p>For primary tumors of the spine, complete surgical resection with negative margins is rarely feasible. In most patients and at most treatment centers, definitive RT is usually the preferred mode of local control in these cases [<a href="#rid55">55</a>]. </p><p>However, improved resection and fusion techniques have made it possible to resect spinal ES in selected patients. For the rare patients who are treated with surgery, the majority will also require postoperative RT to achieve local control. There is also weak evidence to suggest that a complete resection in combination with chemotherapy and/or radiation can potentially improve local control and survival [<a href="#rid56">56-59</a>]. (See <a class="local">'Adjuvant radiation therapy'</a> below.)</p><p>Patients with pelvic primaries have a high complication rate if treated surgically and poorer function if the acetabulum is resected [<a href="#rid60">60</a>], but some studies suggest superior survival with surgical resection. Local control of pelvic primaries must be individualized. There have been improvements in implants and spine fixation techniques that have potentially improved functional outcome following resection of selected primary tumors of the spine and pelvis. The experience in resecting other tumors of the spine and pelvis may be applied to ES, but it requires careful selection of patients and a specialized center with experience in these reconstructions.</p><p>The surgical principles that apply to resection of the primary tumor and reconstruction are similar to those in patients with osteosarcoma and are discussed elsewhere (see  <a class="medical medical_review" href="/d/html/7739.html" rel="external">"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management"</a>). However, there are three main differences between ES and osteosarcoma:</p><p class="bulletIndent1"><span class="glyph">●</span>ES is radiosensitive, while osteosarcoma is much less so.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ES tends to occur in a younger population, where skeletal immaturity and concern for radiation-induced growth inhibition must be considered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ES tends to arise in different areas of the long bones than osteosarcoma (the diaphysis compared with metaphysis  (<a class="graphic graphic_figure graphicRef76662" href="/d/graphic/76662.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef50795" href="/d/graphic/50795.html" rel="external">figure 2</a>)) [<a href="#rid61">61</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Adjuvant radiation therapy</span><span class="headingEndMark"> — </span>RT is usually avoided in patients without residual disease (ie, resected with negative margins) to avoid exposing them to the risk of a radiation-induced malignancy. However, RT is an essential component of therapy for patients undergoing resection if the surgical margins are inadequate, although effective chemotherapy can also reduce the risk of local failure in such patients [<a href="#rid3">3,9</a>]. (See  <a class="medical medical_review" href="/d/html/7748.html" rel="external">"Radiation therapy for Ewing sarcoma family of tumors", section on 'Adjuvant radiation therapy'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT FOR METASTATIC DISEASE</span><span class="headingEndMark"> — </span>Patients with overt metastatic disease at presentation have a significantly worse outcome than do those with localized disease. However, aggressive multimodality therapy can relieve pain, prolong the progression-free interval, and cure some patients of their disease. In a review of 13 different series in which patients with metastatic ES were predominantly treated with chemotherapy, five-year event-free survival (EFS) and overall survival (OS) rates averaged 25 (range 9 to 55) and 33 (range 14 to 61) percent, respectively [<a href="#rid1">1,5,62-72</a>]. The small numbers of patients in each series and the heterogeneity in location and extent of metastatic disease probably account for these wide variations in outcome. (See  <a class="medical medical_review" href="/d/html/7744.html" rel="external">"Clinical presentation, staging, and prognostic factors of Ewing sarcoma", section on 'Disease extent'</a>.)</p><p>In particular, the site of metastatic disease is an important variable. For children with isolated lung and pleural metastases, EFS rates up to 40 percent are reported with multimodality therapy; for metastases involving bone or bone marrow, EFS rates fall to 10 to 20 percent and, for combined sites, to less than 15 percent [<a href="#rid70">70</a>]. Because it can be difficult to predict which patients with metastatic disease will be long-term relapse-free survivors [<a href="#rid63">63</a>], treatment should be administered with curative intent. (See <a class="local">'General treatment principles'</a> above.)</p><p>Several issues are pertinent to patients with metastatic ES:</p><p class="bulletIndent1"><span class="glyph">●</span>What is the optimal initial chemotherapy regimen?</p><p class="bulletIndent1"><span class="glyph">●</span>Does dose intensification or interval compression provide benefit in the initial treatment phase?</p><p class="bulletIndent1"><span class="glyph">●</span>Is there a role for high-dose chemotherapy with hematopoietic cell transplantation as consolidation after initial therapy?</p><p class="bulletIndent1"><span class="glyph">●</span>Is radiation therapy (RT) to sites of metastatic involvement of any benefit?</p><p class="bulletIndent1"><span class="glyph">●</span>How should control of the primary site be approached?</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Chemotherapy</span><span class="headingEndMark"> — </span>Patients with disseminated disease at diagnosis often respond well to the same type of systemic chemotherapy as is used for localized disease. Randomized trials are limited in this population as it accounts for only 25 to 30 percent of patients with ES. Whenever possible, patients with newly diagnosed metastatic ES should be offered enrollment in open clinical trials evaluating novel approaches. In the absence of a clinical trial, regimens similar to those used for the treatment of patients with newly diagnosed localized disease are commonly used (see <a class="local">'Neoadjuvant chemotherapy'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>VDC plus standard-dose I/E</strong> – In contrast to the experience for patients with nonmetastatic disease, specific benefit for the addition of <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> plus <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (I/E) to the <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (VDC) backbone (VDC/IE) has not been shown for patients with metastatic disease at diagnosis [<a href="#rid36">36,65,66,73-75</a>]. Nevertheless, the combination of VDC/IE is commonly employed for this group of patients. An alternative approach of equal validity based on these data is to administer VDC until disease progresses, then switch to I/E. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose-intensified VDC/IE </strong>– In a nonrandomized trial, patients with newly diagnosed metastatic ES were treated with VDC/IE with augmented alkylator doses [<a href="#rid76">76</a>]. Outcomes were similar to patients treated with non-intensified therapy. As a result, this approach has not been propagated in further trials for this population. (See <a class="local">'Other strategies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other approaches</strong> – There is little experience with interval-compressed VDC/IE in the context of metastatic ES, although this regimen is frequently used in this context(see <a class="local">'Interval-compressed VDC/IE'</a> above). </p><p></p><p class="bulletIndent1">In patients with recurrent or refractory ES, initial studies suggested activity for antibodies that target insulin-life growth factor-1 receptor (IGF-1R), such as ganitumab [<a href="#rid77">77-81</a>]. However, in a randomized phase III trial of patients with treatment-naïve metastatic Ewing sarcoma, the addition of ganitumab to interval-compressed chemotherapy with VDC/IE did not improve event-free survival and increased toxicity [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1">High-dose chemotherapy with hematopoietic cell transplantation also remains investigational in patients with metastatic disease. (See <a class="local">'Role for high-dose chemotherapy with hematopoietic cell transplantation?'</a> below.)</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Surgery and radiation therapy</span><span class="headingEndMark"> — </span>Outcomes are best when chemotherapy is combined with optimal local therapy, including radiation and sometimes resection of sites of gross metastatic disease [<a href="#rid71">71,83-85</a>]. This multimodality approach has been most successful for patients with limited pulmonary metastases.</p><p class="headingAnchor" id="H15"><span class="h3">Pulmonary metastases</span><span class="headingEndMark"> — </span>For patients with pulmonary metastases, we offer a multimodality approach that includes chemotherapy and supplemental low-dose whole-lung irradiation, with surgical resection reserved for lung metastases that do not resolve with chemotherapy.</p><p>Patients with a limited number of lung metastases do not share the same dismal prognosis as patients with metastatic disease at other sites (ie, bone or bone marrow). Surgical resection may be undertaken in selected patients [<a href="#rid86">86</a>]. Although complete resection may be possible, chemotherapy is a necessary component of therapy, and five-year survival between 20 and 40 percent can be achieved [<a href="#rid70">70,87,88</a>].</p><p>Supplemental whole-lung radiation also appears to provide a benefit as a consolidation approach for patients with pulmonary metastatic disease, even after a complete response to chemotherapy. Most of the available data supporting radiation in this setting are from nonrandomized series, and patient selection factors confound interpretation of the data. Nevertheless, in patients with a complete response to chemotherapy, low-dose bilateral whole-lung irradiation (12 to 18 Gray [Gy] in daily 1.5 to 2 Gy fractions) may provide added disease control in the lungs without significant pulmonary toxicity. Patients may be evaluated for this approach on an individual basis. This topic is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7748.html" rel="external">"Radiation therapy for Ewing sarcoma family of tumors", section on 'Pulmonary metastases'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Bone and soft tissue metastases</span><span class="headingEndMark"> — </span>Patients with solitary or circumscribed bone or soft tissue lesions can be irradiated at those sites, usually to doses of 45 to 56 Gy, in addition to local control of the primary tumor. However, the likelihood of long-term survival is considerably lower than for patients with isolated pulmonary metastases. More attention has focused on the role of stereotactic body radiation therapy (SBRT) to oligometastatic sites of disease [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/d/html/7748.html" rel="external">"Radiation therapy for Ewing sarcoma family of tumors", section on 'Bone and soft tissue metastases'</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Local control of the primary tumor</span><span class="headingEndMark"> — </span>Local control can pose major issues for patients with metastatic disease. The complete response rate to initial chemotherapy can be increased with subsequent RT or selected excision for all sites of evident disease; however, long-term relapse-free survival is still only achieved in the minority of patients [<a href="#rid63">63</a>].</p><p>The presence of diffuse metastatic disease can make it difficult to justify a large resection, which would necessitate a lengthy period off systemic chemotherapy. For selected patients, resection of the primary tumor may be reconsidered if chemotherapy results in significant volume reduction, particularly if areas of small-volume metastatic disease are also amenable to surgical resection. On the other hand, RT, which is more often considered in patients with metastatic disease, will usually provide adequate local control with acceptable morbidity. If substantial amounts of bone marrow will need to be included in the radiation treatment volume, then radiating the primary tumor may occur first, followed by metastatic site radiation, delayed until the end of systemic therapy to avoid interfering with chemotherapy. (See  <a class="medical medical_review" href="/d/html/7748.html" rel="external">"Radiation therapy for Ewing sarcoma family of tumors", section on 'Management of the primary site'</a>.)</p><p class="headingAnchor" id="H1848596799"><span class="h2">Role for high-dose chemotherapy with hematopoietic cell transplantation?</span><span class="headingEndMark"> — </span>High-dose chemotherapy with hematopoietic cell transplantation does not have a significant role in the treatment of patients who present with metastatic disease, and we do not offer this approach. In randomized studies, the addition of high-dose chemotherapy with hematopoietic cell transplantation did not significantly improve EFS or OS and was associated with significant toxicity [<a href="#rid90">90-92</a>]. Patients who present with metastatic disease should be encouraged to participate in clinical trials that evaluate the use of novel therapeutic approaches.</p><p>Previous observational data were mixed regarding the efficacy and toxicity of high-dose chemotherapy with hematopoietic cell transplantation in this population [<a href="#rid93">93-106</a>], mostly due to variability in the definitions of high-risk patients, in metastatic disease sites, and in regimens. As examples, several prospective observational studies reported EFS rates as high as 50 percent with high-dose chemotherapy and hematopoietic cell transplantation among patients with either isolated pulmonary metastases or multifocal disseminated disease [<a href="#rid99">99,100</a>]. In contrast, other studies evaluating this approach in patients with bone or marrow metastases showed less favorable results, with EFS ranging between 14 and 36 percent [<a href="#rid101">101-106</a>].</p><p>High-dose chemotherapy with hematopoietic cell transplantation was subsequently evaluated in a randomized clinical trial (European Ewing Tumour Working Initiative of National Groups [Euro-EWING] 99 and EWING 2008) [<a href="#rid90">90</a>]. In this trial, 287 patients with isolated pulmonary (lung or pleural) metastatic disease received six cycles of <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (VIDE) and one cycle of vincristine, <a class="drug drug_general" data-topicid="9318" href="/d/drug information/9318.html" rel="external">dactinomycin</a>, and ifosfamide (VAI). Subsequently, patients were randomly assigned to receive either one course of <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a> plus <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a> high-dose chemotherapy followed by autologous hematopoietic cell transplantation, or seven cycles of conventional chemotherapy with VAI followed by whole-lung irradiation. At a median follow-up of approximately eight years, there was no statistically significant difference in EFS between the two groups (eight-year EFS 53 versus 43 percent, hazard ratio [HR] 0.79, 95% CI 0.56-1.1), and OS results were comparable (eight-year OS 55 versus 54 percent, HR 1, 95% CI 0.7-1.44). Additionally, rates of infection as well as gastrointestinal and liver toxicities were higher in the high-dose chemotherapy group and included four deaths versus no deaths in the conventional chemotherapy group.</p><p>Similar results were demonstrated in a separate randomized trial. In an open-label phase III trial (Ewing 2008R3), 109 patients with metastatic ES (excluding those with pulmonary metastases only) were treated with six cycles of VIDE and consolidation therapy with eight cycles of <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, actinomycin D, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. Patients were then randomly assigned to either <a class="drug drug_general" data-topicid="134625" href="/d/drug information/134625.html" rel="external">treosulfan</a> plus <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a> high-dose chemotherapy followed by hematopoietic cell transplantation or no further treatment. At median follow-up of 3.3 years, the addition of high-dose chemotherapy with hematopoietic cell transplantation did not improve three-year EFS (21 versus 19 percent, HR 0.85, 95% CI 0.55-1.32) [<a href="#rid92">92</a>]. However, in a posthoc analysis of the subset of 41 patients less than 14 years of age, a potential EFS benefit for this approach was demonstrated (three-year EFS 39 versus 9 percent, HR 0.4, 95% CI 0.19-0.87). Given the limited sample size and lack of preplanned analysis for this subgroup, these results should be interpreted with caution. </p><p class="headingAnchor" id="H24921961"><span class="h1">POSTTREATMENT SURVEILLANCE</span><span class="headingEndMark"> — </span>There are no prospective data that address the appropriate schedule or selection of tests for surveillance for patients with ES after initial treatment for localized disease. Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) [<a href="#rid107">107</a>] and from the Children's Oncology Group (COG) [<a href="#rid108">108</a>] recommend physical examination, a complete blood count, chest imaging, and surveillance imaging for primary site and distant recurrences every three months for two years, every six months for years 3 to 5, and annually thereafter  (<a class="graphic graphic_table graphicRef68393" href="/d/graphic/68393.html" rel="external">table 2</a>) [<a href="#rid107">107,109</a>]. </p><p>Local imaging of the primary site depends upon the specific site and prior local therapy. For example:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a metal endoprosthesis are usually imaged with plain radiographs. Magnetic resonance imaging (MRI) of the primary site may offer little in the way of diagnostic information if a metal endoprosthesis is present. In addition, some patients treated with extendible endoprostheses cannot have an MRI. MRI and computed tomography (CT) techniques with metal subtraction are available but may not be necessary for most patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients treated with prior radiation therapy (RT), MRI may continue to be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with chest wall primary tumors, a chest CT scan or chest radiograph may be used, depending upon level of concern for risk of recurrence. </p><p></p><p>For surveillance imaging of potential distant metastases, we perform a chest radiograph, with subsequent evaluation using chest CT for abnormal imaging. Patients with symptoms or abnormal imaging or those who are planning surgical interventions may also be offered fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT. A meta-analysis study showed that FDG-PET and PET-CT have a high accuracy in detecting distant metastases and postoperative recurrences in patients with ES [<a href="#rid110">110</a>].</p><p>The appropriate duration of follow-up is unknown. Given the possibility of late relapse (although the vast majority of recurrences are observed within 10 years) and late development of treatment-related complications such as second neoplasms, some suggest that the patient be followed indefinitely [<a href="#rid111">111</a>]. There are no definite protocols for this, but the authors suggest that survivors have ongoing surveillance for late effects or late relapse. (See <a class="local">'Evaluation'</a> below.)</p><p>Physicians performing posttreatment surveillance must be cognizant of concerns for radiation exposure and the risk for secondary malignancies, particularly in younger individuals. (See <a class="local">'Complications in long-term survivors'</a> below and  <a class="medical medical_review" href="/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">RECURRENT DISEASE</span><span class="headingEndMark"> — </span>The majority of relapses occur within two years of initial diagnosis, but late relapse is not uncommon [<a href="#rid112">112-114</a>]. In a report from the Childhood Cancer Survivor Study (CCSS), the 20-year cumulative incidence of a late recurrence among five-year survivors of ES was 13 percent [<a href="#rid114">114</a>]. For this reason, it is advisable that patients be followed for the potential of late relapse indefinitely. (See <a class="local">'Posttreatment surveillance'</a> above.)</p><p>In general, survival after an early relapse is poor, with few survivors among those who relapse within two years of therapy. In contrast, up to 15 to 20 percent of those who relapse later may survive long-term [<a href="#rid115">115,116</a>]. Other prognostic factors for death in patients with recurrent ES include recurrence at combined local and distant sites, and an elevated lactate dehydrogenase (LDH) at initial diagnosis [<a href="#rid115">115,116</a>]. </p><p class="headingAnchor" id="H19"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Symptoms at the primary site or elsewhere should raise concern and be appropriately investigated. Patients with a suspected recurrence should undergo evaluation both of the primary site and for the presence of metastatic disease before a treatment plan is formulated. The majority of patients with a local recurrence have either gross or microscopic metastatic disease.</p><p>The documentation of a local recurrence can be difficult. In patients with metallic endoprostheses, MRI and CT evaluation can be distorted by metal artifact, although this is improved with contemporary MRI and CT imaging technology. In patients who are treated with certain extendable "growing" prostheses, MRI may be contraindicated. The interpretation of irradiated areas on imaging studies can be challenging because of the changes in bone caused by the radiation. Soft tissue masses may represent residual fibrosis rather than recurrent tumor. The evaluation of intraosseous sites is even more difficult since the response to prior therapy and the variability in reossification complicate the interpretation of radiographic studies. Progressive cortical destruction or increasing radiolucent areas suggest local recurrence, as do bone scans that demonstrate increased radiotracer uptake. Positron emission tomography (PET) scans may be useful to assess the likelihood of recurrence at a site that is suspicious on cross-sectional radiographic imaging. Ultrasound can also be useful to assess for soft tissue masses around an endoprosthesis. The decision to biopsy a site of suspected recurrent local or metastatic disease depends upon patient history and the level of evidence from imaging studies. Open bone biopsies can be associated with local morbidity (ie, wound complications and bone fracture), and needle biopsies may suffice.</p><p class="headingAnchor" id="H20"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Although the prognosis for patients with recurrent disease is poor, some patients can be successfully salvaged, particularly patients with late relapses [<a href="#rid117">117,118</a>]. Sites of recurrence, prior treatment, and relapse-free interval affect remaining treatment choices. Most patients with recurrent disease will receive systemic therapy prior to attempts at additional local control measures. Patients relapsing after a lengthy disease-free interval off chemotherapy may respond again to the same agents used as part of initial therapy</p><p class="headingAnchor" id="H4254369245"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>For patients with an initial recurrence of ES, we suggest either high-dose <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> or <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> plus <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> (IT) rather than <a class="drug drug_general" data-topicid="10007" href="/d/drug information/10007.html" rel="external">topotecan</a> plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (TC). For patients who decline or are ineligible for either of these regimens due to potential toxicities, TC is an appropriate alternative. Since treatment intent is generally palliative and each chemotherapy regimen carries a different toxicity profile, clinicians should discuss the risks and benefits of each treatment with their patients. </p><p>Based on data from initial studies [<a href="#rid119">119-124</a>], an international randomized phase II/III trial (rEECur) was conducted in 439 patients with recurrent or primary refractory ES [<a href="#rid125">125</a>]. In this study, patients were randomly assigned to one of four different chemotherapy regimens: high-dose <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>; TC; IT; and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> (GD). During the first two interim analyses, IT and GD were dropped from further study as these regimens were predicted to have a lower probability of superiority compared with the remaining arms. Continued recruitment for this trial is ongoing for other regimens including <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> and evaluation of targeted therapy (ifosfamide plus <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>).</p><p>The phase III portion of the trial compared high-dose <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> with TC in 146 patients. At a median follow-up of 40 months, high-dose ifosfamide demonstrated higher event-free survival (EFS; median 5.7 versus 3.5 months; six-month EFS 47 versus 37 percent, hazard ratio [HR] 0.73, 95% CI 0.51-1.05) and overall survival (OS; median 15.4 versus 10.5 months; one-year OS 55 versus 45 percent, HR 0.73, 95% CI 0.50-1.08); this difference, while potentially clinically significant, was not statistically significant. In this Bayesian trial design, there was a 96 percent probability that high-dose ifosfamide was superior to TC. Objective response rates were also higher for high-dose ifosfamide compared with TC (30 versus 21 percent). In a subgroup analysis, high-dose ifosfamide conferred a higher EFS benefit versus TC for children (age &lt;14 years) compared with adolescents and adults (age ≥14 years). However, compared with TC, high-dose ifosfamide had higher rates of grade ≥3 neurotoxicity (7 versus 0 percent), nephrotoxicity (8 versus 0 percent), and infection (14 versus 8 percent), leading to higher rates of treatment discontinuation. Other grade ≥3 toxicity rates were similar between the two treatment arms including febrile neutropenia (25 versus 26 percent), vomiting (1 percent each), nausea (3 versus 0 percent), and diarrhea (1 percent each). </p><p>Due to the trial design of rEEcur, it is difficult to compare the efficacy of high dose <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> with IT. These two regimens were not directly compared in the randomized phase III portion of the study, and the dropping of the IT treatment arm implies that its efficacy was inferior to high-dose ifosfamide. However, in preliminary results of an interim analysis of rEEcur, at median follow-up of 9 months, among the 127 patients treated with IT arm, median EFS and OS were 4.7 and 13.9 months, respectively, which were only slightly lower than that seen with high-dose ifosfamide (5.7 and 15.7 months, respectively) but higher than that seen with TC (3.5 and 10.5 months, respectively) [<a href="#rid126">126</a>]. Grade ≥3 toxicity for IT were diarrhea (17 percent), nausea, vomiting (6 percent each), fatigue, and febrile neutropenia (3 percent each). Since data on patient-reported outcomes are limited, toxicity profiles are different for each regimens, and treatment is generally palliative in this situation, both IT and TC remain reasonable options in patients with recurrent ES. </p><p class="headingAnchor" id="H1044947757"><span class="h3">Targeted therapies</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">Cabozantinib</a>, an inhibitor of the vascular endothelial growth factor receptor (VEGFR) and MET signaling pathways, is an alternative option for subsequent-line therapy in patients with relapsed/refractory or metastatic disease. Cabozantinib has demonstrated activity in patients with advanced ES, with an objective response rate of 26 percent and median progression-free survival of five months in one phase II trial (CABONE) [<a href="#rid127">127</a>]. </p><p class="headingAnchor" id="H3648840048"><span class="h3">Local therapies</span><span class="headingEndMark"> — </span>Local management of a local recurrence usually includes surgery (and possibly an amputation if the local recurrence involves an irradiated extremity), radiation therapy (RT), or both. RT to bone lesions usually provides pain relief, while surgery can eradicate disease in some cases with limited isolated lung metastases [<a href="#rid87">87</a>]. As an example, one study of 26 patients with local recurrence showed that the survival at five years post local recurrence was 28 percent. Better survival outcomes were seen in those who did not have metastases at diagnosis of the recurrence, had a surgical treatment for the recurrence, and had complete eradication of all disease [<a href="#rid128">128</a>].</p><p class="headingAnchor" id="H2029125342"><span class="h2">Investigational agents</span><span class="headingEndMark"> — </span>Patients with recurrent or advanced ES should be encouraged to participate in clinical trials, where available. Future therapies will likely emerge as the fundamental biology of the fusion oncoproteins driving this disease is better understood [<a href="#rid11">11,129</a>]. (See  <a class="medical medical_review" href="/d/html/7742.html" rel="external">"Epidemiology, pathology, and molecular genetics of Ewing sarcoma"</a> and  <a class="medical medical_review" href="/d/html/7744.html" rel="external">"Clinical presentation, staging, and prognostic factors of Ewing sarcoma", section on 'Prognostic factors'</a>.)</p><p>In a phase II study of adults with relapsed ES, <a class="drug drug_general" data-topicid="128469" href="/d/drug information/128469.html" rel="external">lurbinectedin</a> demonstrated an objective response rate of 14 percent [<a href="#rid130">130</a>].</p><p>Examples of other drugs under investigation include agents targeting cyclin D1/CKD4 inhibitors [<a href="#rid131">131</a>], lysine specific demethylase 1 (LSD1) [<a href="#rid132">132</a>], and RNA helicase [<a href="#rid133">133</a>]. </p><p class="headingAnchor" id="H21"><span class="h1">COMPLICATIONS IN LONG-TERM SURVIVORS</span><span class="headingEndMark"> — </span>Although the survival of patients with ES has improved steadily since the 1970s, long-term survivors have considerable burden of the late effects of their therapy [<a href="#rid10">10,52,111,134-136</a>]. These include subsequent primary cancers, pathologic fractures, other radiation-associated complications (wound complications, pulmonary fibrosis, neuropathy, limb leg discrepancy, femoral head necrosis), and chemotherapy-related complications (subsequent primary cancers, reduced fertility, renal insufficiency, and cardiomyopathy) [<a href="#rid134">134,137</a>].</p><p>Secondary myelodysplasia (MDS) and leukemia are particular concerns for this population [<a href="#rid103">103,106,138-140</a>]. This was illustrated in a report from the Children's Oncology Group (COG) of 578 children with ES who were treated with three different regimens over a six-year period [<a href="#rid138">138</a>]. Overall, 11 children developed secondary MDS/acute myeloid leukemia (AML), and the cumulative risk was significantly higher among children treated with a regimen incorporating higher doses of <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> as compared with those receiving standard-dose <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, doxorubicin, cyclophosphamide, and <a class="drug drug_general" data-topicid="9318" href="/d/drug information/9318.html" rel="external">dactinomycin</a> (VDCA) with or without ifosfamide plus <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (11, 0.9, and 0.4 percent at five years, respectively).</p><p>The health status of long-term (≥5 years) survivors was addressed in a cohort study of 568 individuals who were diagnosed with ES before age 21 from 1970 to 1986, including a subset of 403 patients who were participating in the Childhood Cancer Survivor Study (CCSS) [<a href="#rid136">136</a>]. Cumulative mortality among all survivors was 25 percent at 25 years after diagnosis, and the cumulative incidence of secondary malignancy was 9 percent. Disease progression/recurrence accounted for 60 percent of all deaths, while other causes included secondary neoplasms, cardiac disease, other medical causes, and pulmonary disease. The cumulative mortality attributed to subsequent malignant neoplasms and cardiopulmonary disease potentially attributed to treatment was 8.3 percent at 25 years. In addition, compared with their siblings, survivors had significantly higher rates of severe, disabling, or chronic health conditions, significantly lower fertility rates, and higher rates of self-reported moderate to extreme adverse health status.</p><p>It is anticipated that the adoption of tailored radiation ports in the last 15 years (as opposed to whole-bone ports used in the period 1960 to 1980), the use of lower and risk-adopted radiation therapy (RT) doses, an appreciation of the rise in radiation-induced subsequent primary cancer risk with doses above 60 Gray (Gy), and the increased use of surgical resection in the population with nonmetastatic disease will all reduce the risk of late effects. (See  <a class="medical medical_review" href="/d/html/7748.html" rel="external">"Radiation therapy for Ewing sarcoma family of tumors", section on 'Late effects'</a>.)</p><p>Nevertheless, the relatively high complication rates seen with many of these earlier treatment approaches, the delayed nature of many of the complications, and the possibility that trends in chemotherapy intensification may alter the pattern of secondary malignancies [<a href="#rid135">135</a>] underscore the need for long-term follow-up. Long-term follow-up guidelines after treatment of childhood malignancy are available from <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.survivorshipguidelines.org%2F&amp;token=S16MTPPY6cpS0A68kxrRsQOkLnEIm8%2BQaMhQyNKCcl%2BJTIC9BC9aNpypysLPfb9F&amp;TOPIC_ID=7740" target="_blank">COG</a>.</p><p class="headingAnchor" id="H3186771888"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119797.html" rel="external">"Society guideline links: Soft tissue sarcoma"</a> and  <a class="medical medical_society_guidelines" href="/d/html/134680.html" rel="external">"Society guideline links: Bone sarcomas"</a>.)</p><p class="headingAnchor" id="H113086554"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83151.html" rel="external">"Patient education: Ewing sarcoma (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/83150.html" rel="external">"Patient education: Bone cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General treatment principles</strong> – Patients with Ewing sarcoma (ES) require referral to centers that have multidisciplinary teams of sarcoma specialists. With rare exception, systemic combination chemotherapy and definitive local therapy are required in all patients, and care should be coordinated among the medical/pediatric oncologist, surgeon, and radiation therapist. (See <a class="local">'General treatment principles'</a> above.)</p><p></p><p class="bulletIndent1">Treatment of adults with ES should be guided by the same general principles as are used for younger individuals. (See <a class="local">'Adult patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy (chemotherapy)</strong> – For patients with localized ES, we recommend initial chemotherapy with alternating cycles of <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>/<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>/<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>/<a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (VDC/IE) rather than vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>), as this regimen improves overall survival (OS) and is shorter in duration with less toxicity. (See <a class="local">'Selection of therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients age &lt;18 years</strong> – For patients age &lt;18 years with localized ES, we recommend interval-compressed VDC/IE given every two weeks with hematopoietic growth factor support  (<a class="graphic graphic_table graphicRef110260" href="/d/graphic/110260.html" rel="external">table 1</a>), rather than every three weeks without growth factor support (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>), as this approach improved event-free survival (EFS) and OS without increased toxicity or higher risk of second (subsequent) malignant neoplasms in a phase III trial (AEWS0031). (See <a class="local">'Interval-compressed VDC/IE'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients age ≥18 years</strong> – For patients age ≥18 years, we offer VDC/IE either every two weeks with hematopoietic growth factor support or every three weeks without growth factor support. A subgroup analysis of this population in AEWS0031, which mainly enrolled younger patients, did not demonstrate a difference in EFS between the two treatment arms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local control</strong> – Local control for ES can be achieved by surgery, radiation therapy (RT), or both. The choice between RT and surgery is decided based on patient characteristics, potential harm and benefit of the treatment options, and patient preference. (See <a class="local">'Local treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with nonmetastatic disease, surgical resection is preferred if it is anticipated that a complete resection with negative margins can be achieved and a functional reconstruction is possible. Patients who lack a function-preserving surgical option because of tumor location or extent may be offered RT as an alternative to resection. Surgery is also preferred for lesions arising in dispensable bones (eg, fibula, rib, small lesions of the hands or feet) and to avoid the risk of secondary radiation-associated sarcomas. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A combination of radiation and surgery is reserved for cases in which negative margins cannot be achieved while still preserving function. (See  <a class="medical medical_review" href="/d/html/7748.html" rel="external">"Radiation therapy for Ewing sarcoma family of tumors", section on 'Adjuvant radiation therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following local treatment, chemotherapy is usually continued (the same alternating VDC/IE regimen), typically for several months  (<a class="graphic graphic_table graphicRef110260" href="/d/graphic/110260.html" rel="external">table 1</a>). (See <a class="local">'Interval-compressed VDC/IE'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metastatic disease</strong> – Patients with clinically detectable metastatic disease at initial presentation also require multimodality therapy. Patients with advanced disease typically should be approached with potentially curative treatment. Up to 40 percent of children with limited pulmonary metastatic disease who undergo intensive chemotherapy and pulmonary resection with or without RT may be long-term survivors. The prognosis for other subsets of patients with advanced disease is less favorable. (See <a class="local">'Treatment for metastatic disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with pulmonary-only metastases, we offer a multimodality approach that includes chemotherapy and supplemental low-dose whole-lung irradiation, with surgical resection for lung metastases that do not resolve completely with chemotherapy. Adults with pulmonary-only metastases may be treated similarly, but data for this approach are limited. (See  <a class="medical medical_review" href="/d/html/7748.html" rel="external">"Radiation therapy for Ewing sarcoma family of tumors", section on 'Pulmonary metastases'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-dose chemotherapy with hematopoietic cell transplantation does not have a significant role for patients with metastatic ES, and we do not offer this approach as standard of care in the United States. (See <a class="local">'Role for high-dose chemotherapy with hematopoietic cell transplantation?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posttreatment surveillance</strong> – The majority of relapses occur within two years of initial diagnosis, but later relapses have been observed. For all ES of bone or soft tissue, there are no prospective data that address the appropriate schedule or selection of tests for surveillance after initial treatment for localized disease. (See <a class="local">'Posttreatment surveillance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) and from the Children's Oncology Group (COG)  (<a class="graphic graphic_table graphicRef68393" href="/d/graphic/68393.html" rel="external">table 2</a>) recommend physical examination, a complete blood count, chest imaging, and local imaging of the primary site every three months for two years, every six months for years 3 to 5, and annually thereafter. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Long-term follow-up (lifelong) is needed following therapy because disease relapse, treatment-related complications, and second malignancies all occur beyond five years after treatment is initiated. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent disease</strong> – Although the prognosis for patients with recurrent disease is poor, some patients can be successfully salvaged. The sites of recurrence, prior treatment, and relapse-free interval affect the remaining treatment choices. Most patients with recurrent disease will receive systemic therapy prior to attempts at additional local control measures. (See <a class="local">'Recurrent disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an initial recurrence of ES, we suggest either high-dose <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> or <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> plus <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> (IT) rather than <a class="drug drug_general" data-topicid="10007" href="/d/drug information/10007.html" rel="external">topotecan</a> plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (TC) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients who decline or are ineligible either of these regimens due to potential toxicities, TC is an appropriate alternative. Since treatment intent is palliative and each chemotherapy regimen carries a different toxicity profile, clinicians should discuss the risks and benefits of each treatment with their patients. (See <a class="local">'Chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">Cabozantinib</a> is an alternative option for subsequent-line therapy in patients with relapsed/refractory or metastatic disease. (See <a class="local">'Targeted therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long term</strong> <strong>toxicities in survivors of ES</strong> – The survival of patients with ES has steadily improved; however, long-term survivors have considerable burden of the late effects of their therapy. These include subsequent primary cancers, pathologic fractures, other radiation-associated complications (wound complications, pulmonary fibrosis, neuropathy, limb leg discrepancy, femoral head necrosis), and chemotherapy-related complications (subsequent primary cancers, reduced fertility, renal insufficiency, and cardiomyopathy). (See <a class="local">'Complications in long-term survivors'</a> above.)</p><p></p><p class="bulletIndent1">Long-term follow-up guidelines after treatment of childhood malignancy are available from the COG. (See  <a class="medical medical_review" href="/d/html/7748.html" rel="external">"Radiation therapy for Ewing sarcoma family of tumors", section on 'Late effects'</a>.)</p><p></p><p class="headingAnchor" id="H1223328301"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David C Harmon, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 1998; 16:3628.</a></li><li><a class="nounderline abstract_t">Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001; 19:1818.</a></li><li><a class="nounderline abstract_t">Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990; 8:1664.</a></li><li><a class="nounderline abstract_t">Obata H, Ueda T, Kawai A, et al. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer 2007; 109:767.</a></li><li><a class="nounderline abstract_t">Donaldson SS, Torrey M, Link MP, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42:125.</a></li><li><a class="nounderline abstract_t">Nilbert M, Saeter G, Elomaa I, et al. Ewing's sarcoma treatment in Scandinavia 1984-1990--ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV. Acta Oncol 1998; 37:375.</a></li><li><a class="nounderline abstract_t">Raney RB, Asmar L, Newton WA Jr, et al. Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. J Clin Oncol 1997; 15:574.</a></li><li><a class="nounderline abstract_t">Ferrari S, Mercuri M, Rosito P, et al. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity. J Chemother 1998; 10:484.</a></li><li><a class="nounderline abstract_t">Kinsella TJ, Miser JS, Waller B, et al. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys 1991; 20:389.</a></li><li><a class="nounderline abstract_t">Rodríguez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 2007; 110:375.</a></li><li><a class="nounderline abstract_t">Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010; 11:184.</a></li><li><a class="nounderline abstract_t">Arai Y, Kun LE, Brooks MT, et al. Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Biol Phys 1991; 21:1501.</a></li><li><a class="nounderline abstract_t">Dunst J, Sauer R, Burgers JM, et al. Radiation therapy as local treatment in Ewing's sarcoma. Results of the Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. Cancer 1991; 67:2818.</a></li><li><a class="nounderline abstract_t">Bacci G, Balladelli A, Forni C, et al. Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. Cancer 2007; 109:780.</a></li><li><a class="nounderline abstract_t">Ahmed SK, Robinson SI, Okuno SH, et al. Adult Ewing sarcoma: survival and local control outcomes in 36 patients with metastatic disease. Am J Clin Oncol 2014; 37:423.</a></li><li><a class="nounderline abstract_t">Pretz JL, Barysauskas CM, George S, et al. Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy. Oncologist 2017; 22:1265.</a></li><li><a class="nounderline abstract_t">Picci P, Böhling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol 1997; 15:1553.</a></li><li><a class="nounderline abstract_t">Siegel RD, Ryan LM, Antman KH. Adults with Ewing's sarcoma. An analysis of 16 patients at the Dana-Farber Cancer Institute. Am J Clin Oncol 1988; 11:614.</a></li><li><a class="nounderline abstract_t">Sinkovics JG, Plager C, Ayala AG, et al. Ewing sarcoma: its course and treatment in 50 adult patients. Oncology 1980; 37:114.</a></li><li><a class="nounderline abstract_t">Klaassen R, Sastre-Garau X, Aurias A, et al. [Ewing's sarcoma of bone in adults: an anatomic-clinical study of 30 cases]. Bull Cancer 1992; 79:161.</a></li><li><a class="nounderline abstract_t">Verrill MW, Judson IR, Wiltshaw E, et al. The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. Ann Oncol 1997; 8:1099.</a></li><li><a class="nounderline abstract_t">Ahmed SK, Robinson SI, Okuno SH, et al. Adult ewing sarcoma: survival and local control outcomes in 102 patients with localized disease. Sarcoma 2013; 2013:681425.</a></li><li><a class="nounderline abstract_t">Karski EE, Matthay KK, Neuhaus JM, et al. Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiol 2013; 37:29.</a></li><li><a class="nounderline abstract_t">Wagner MJ, Gopalakrishnan V, Ravi V, et al. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist 2017; 22:1271.</a></li><li><a class="nounderline abstract_t">Shamberger RC, Laquaglia MP, Krailo MD, et al. Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection. J Thorac Cardiovasc Surg 2000; 119:1154.</a></li><li><a class="nounderline abstract_t">Denbo JW, Shannon Orr W, Wu Y, et al. Timing of surgery and the role of adjuvant radiotherapy in ewing sarcoma of the chest wall: a single-institution experience. Ann Surg Oncol 2012; 19:3809.</a></li><li><a class="nounderline abstract_t">Mirzaei L, Kaal SE, Schreuder HW, Bartels RH. The Neurological Compromised Spine Due to Ewing Sarcoma. What First: Surgery or Chemotherapy? Therapy, Survival, and Neurological Outcome of 15 Cases With Primary Ewing Sarcoma of the Vertebral Column. Neurosurgery 2015; 77:718.</a></li><li><a class="nounderline abstract_t">Gaspar N, Hawkins DS, Dirksen U, et al. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. J Clin Oncol 2015; 33:3036.</a></li><li><a class="nounderline abstract_t">Jürgens H, Bier V, Harms D, et al. Malignant peripheral neuroectodermal tumors. A retrospective analysis of 42 patients. Cancer 1988; 61:349.</a></li><li><a class="nounderline abstract_t">Ahmad R, Mayol BR, Davis M, Rougraff BT. Extraskeletal Ewing's sarcoma. Cancer 1999; 85:725.</a></li><li><a class="nounderline abstract_t">Gururangan S, Marina NM, Luo X, et al. Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy. J Pediatr Hematol Oncol 1998; 20:55.</a></li><li><a class="nounderline abstract_t">Castex MP, Rubie H, Stevens MC, et al. Extraosseous localized ewing tumors: improved outcome with anthracyclines--the French society of pediatric oncology and international society of pediatric oncology. J Clin Oncol 2007; 25:1176.</a></li><li><a class="nounderline abstract_t">Cash T, McIlvaine E, Krailo MD, et al. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 2016; 63:1771.</a></li><li><a class="nounderline abstract_t">Brennan B, Kirton L, Marec-Bérard P, et al. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet 2022; 400:1513.</a></li><li><a class="nounderline abstract_t">Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990; 8:1514.</a></li><li><a class="nounderline abstract_t">Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694.</a></li><li><a class="nounderline abstract_t">Whelan J, Le Deley MC, Dirksen U, et al. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol 2018; :JCO2018782516.</a></li><li><a class="nounderline abstract_t">Mascarenhas L, Felgenhauer JL, Bond MC, et al. Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer 2016; 63:493.</a></li><li><a class="nounderline abstract_t">Leavey PJ, Laack NN, Krailo MD, et al. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol 2021; 39:4029.</a></li><li><a class="nounderline abstract_t">Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:4148.</a></li><li><a class="nounderline abstract_t">Cash T, Krailo MD, Buxton A, et al. Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy: A long-term follow-up report from Children’s Oncology Group study AEWS0031. J Clin Oncol 2022; 40;16S.</a></li><li><a class="nounderline abstract_t">Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000; 36:87.</a></li><li><a class="nounderline abstract_t">Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol 2009; 27:2536.</a></li><li><a class="nounderline abstract_t">Guo W, Li D, Tang X, et al. Reconstruction with modular hemipelvic prostheses for periacetabular tumor. Clin Orthop Relat Res 2007; 461:180.</a></li><li><a class="nounderline abstract_t">Fan H, Fu J, Li X, et al. Implantation of customized 3-D printed titanium prosthesis in limb salvage surgery: a case series and review of the literature. World J Surg Oncol 2015; 13:308.</a></li><li><a class="nounderline abstract_t">Woo SH, Sung MJ, Park KS, Yoon TR. Three-dimensional-printing Technology in Hip and Pelvic Surgery: Current Landscape. Hip Pelvis 2020; 32:1.</a></li><li><a class="nounderline abstract_t">Fujiwara T, Lex JR, Stevenson JD, et al. Surgical treatment for pelvic Ewing sarcoma: What is a safe and functional acetabular reconstruction when combined with modern multidisciplinary treatments? J Surg Oncol 2019; 120:985.</a></li><li><a class="nounderline abstract_t">DuBois SG, Krailo MD, Gebhardt MC, et al. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. Cancer 2015; 121:467.</a></li><li><a class="nounderline abstract_t">Shankar AG, Pinkerton CR, Atra A, et al. Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG). Eur J Cancer 1999; 35:1698.</a></li><li><a class="nounderline abstract_t">Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003; 55:168.</a></li><li><a class="nounderline abstract_t">Werier J, Yao X, Caudrelier JM, et al. A systematic review of optimal treatment strategies for localized Ewing's sarcoma of bone after neo-adjuvant chemotherapy. Surg Oncol 2016; 25:16.</a></li><li><a class="nounderline abstract_t">Bacci G, Forni C, Longhi A, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004; 40:73.</a></li><li><a class="nounderline abstract_t">Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000; 18:4.</a></li><li><a class="nounderline abstract_t">Daw NC, Laack NN, McIlvaine EJ, et al. Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group. Ann Surg Oncol 2016; 23:3541.</a></li><li><a class="nounderline abstract_t">Vogin G, Helfre S, Glorion C, et al. Local control and sequelae in localised Ewing tumours of the spine: a French retrospective study. Eur J Cancer 2013; 49:1314.</a></li><li><a class="nounderline abstract_t">Charest-Morin R, Dirks MS, Patel S, et al. Ewing Sarcoma of the Spine: Prognostic Variables for Survival and Local Control in Surgically Treated Patients. Spine (Phila Pa 1976) 2018; 43:622.</a></li><li><a class="nounderline abstract_t">Sciubba DM, Okuno SH, Dekutoski MB, Gokaslan ZL. Ewing and osteogenic sarcoma: evidence for multidisciplinary management. Spine (Phila Pa 1976) 2009; 34:S58.</a></li><li><a class="nounderline abstract_t">Oliveira C, Vital L, Serdoura F, et al. Spondylectomy for Primary Ewing Lumbar Sarcoma in Children. Rev Bras Ortop (Sao Paulo) 2020; 55:649.</a></li><li><a class="nounderline abstract_t">Sewell MD, Tan KA, Quraishi NA, et al. Systematic Review of En Bloc Resection in the Management of Ewing's Sarcoma of the Mobile Spine with Respect to Local Control and Disease-Free Survival. Medicine (Baltimore) 2015; 94:e1019.</a></li><li><a class="nounderline abstract_t">Puri A, Gulia A, Jambhekar NA, Laskar S. Results of surgical resection in pelvic Ewing's sarcoma. J Surg Oncol 2012; 106:417.</a></li><li class="breakAll">Ginsberg JP, Woo SY, Hicks MJ, Horowitz ME. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Principles and Practice of Pediatric Oncology, 4th ed, Pizzo PA, Poplack DG (Eds), Lippincott, Williams and Wilkins, Philadelphia 2000.</li><li><a class="nounderline abstract_t">Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 1995; 13:2796.</a></li><li><a class="nounderline abstract_t">Pinkerton CR, Bataillard A, Guillo S, et al. Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer 2001; 37:1338.</a></li><li><a class="nounderline abstract_t">Hayes FA, Thompson EI, Parvey L, et al. Metastatic Ewing's sarcoma: remission induction and survival. J Clin Oncol 1987; 5:1199.</a></li><li><a class="nounderline abstract_t">Sandoval C, Meyer WH, Parham DM, et al. Outcome in 43 children presenting with metastatic Ewing sarcoma: the St. Jude Children's Research Hospital experience, 1962 to 1992. Med Pediatr Oncol 1996; 26:180.</a></li><li><a class="nounderline abstract_t">Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998; 9:275.</a></li><li><a class="nounderline abstract_t">Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer 1997; 33:1061.</a></li><li><a class="nounderline abstract_t">Deméocq F, Oberlin O, Benz-Lemoine E, et al. Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP). Cancer Chemother Pharmacol 1989; 24 Suppl 1:S45.</a></li><li><a class="nounderline abstract_t">Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. J Clin Oncol 1999; 17:180.</a></li><li><a class="nounderline abstract_t">Paulussen M, Ahrens S, Craft AW, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998; 16:3044.</a></li><li><a class="nounderline abstract_t">Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66:887.</a></li><li><a class="nounderline abstract_t">Brunetto AL, Castillo LA, Petrilli AS, et al. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. Pediatr Blood Cancer 2015; 62:1747.</a></li><li><a class="nounderline abstract_t">Wexler LH, DeLaney TF, Tsokos M, et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 1996; 78:901.</a></li><li><a class="nounderline abstract_t">Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004; 22:2873.</a></li><li><a class="nounderline abstract_t">Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26:4385.</a></li><li><a class="nounderline abstract_t">Goldsby RE, Ablin AR. Surviving childhood cancer; now what? Controversies regarding long-term follow-up. Pediatr Blood Cancer 2004; 43:211.</a></li><li><a class="nounderline abstract_t">Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011; 29:4534.</a></li><li><a class="nounderline abstract_t">Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011; 29:4541.</a></li><li><a class="nounderline abstract_t">Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012; 30:1849.</a></li><li><a class="nounderline abstract_t">Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 2013; 14:371.</a></li><li><a class="nounderline abstract_t">Naing A, LoRusso P, Fu S, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 2012; 18:2625.</a></li><li><a class="nounderline abstract_t">DuBois SG, Krailo MD, Glade-Bender J, et al. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol 2023; 41:2098.</a></li><li><a class="nounderline abstract_t">Miser JS, Kinsella TJ, Triche TJ, et al. Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance. J Clin Oncol 1988; 6:484.</a></li><li><a class="nounderline abstract_t">Pilepich MV, Vietti TJ, Nesbit ME, et al. Radiotherapy and combination chemotherapy in advanced Ewing's Sarcoma-Intergroup study. Cancer 1981; 47:1930.</a></li><li><a class="nounderline abstract_t">Haeusler J, Ranft A, Boelling T, et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010; 116:443.</a></li><li><a class="nounderline abstract_t">Raciborska A, Bilska K, Rychłowska-Pruszyńska M, et al. Management and follow-up of Ewing sarcoma patients with isolated lung metastases. J Pediatr Surg 2016; 51:1067.</a></li><li><a class="nounderline abstract_t">Bacci G, Briccoli A, Picci P, Ferrari S. Metachronous pulmonary metastases resection in patients with Ewing's sarcoma initially treated with adjuvant or neoadjuvant chemotherapy. Eur J Cancer 1995; 31A:999.</a></li><li><a class="nounderline abstract_t">Dunst J, Paulussen M, Jürgens H. Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies. Strahlenther Onkol 1993; 169:621.</a></li><li><a class="nounderline abstract_t">Brown LC, Lester RA, Grams MP, et al. Stereotactic body radiotherapy for metastatic and recurrent ewing sarcoma and osteosarcoma. Sarcoma 2014; 2014:418270.</a></li><li><a class="nounderline abstract_t">Dirksen U, Brennan B, Le Deley MC, et al. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol 2019; 37:3192.</a></li><li><a class="nounderline abstract_t">Haveman LM, van Ewijk R, van Dalen EC, et al. High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma. Cochrane Database Syst Rev 2021; 9:CD011405.</a></li><li><a class="nounderline abstract_t">Koch R, Gelderblom H, Haveman L, et al. High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. J Clin Oncol 2022; 40:2307.</a></li><li><a class="nounderline abstract_t">Czyzewski EA, Goldman S, Mundt AJ, et al. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study. Int J Radiat Oncol Biol Phys 1999; 44:569.</a></li><li><a class="nounderline abstract_t">Perentesis J, Katsanis E, DeFor T, et al. Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant 1999; 24:609.</a></li><li><a class="nounderline abstract_t">Atra A, Whelan JS, Calvagna V, et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997; 20:843.</a></li><li><a class="nounderline abstract_t">Prete A, Rosito P, Alvisi P, et al. G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-risk Ewing sarcoma of childhood. Bone Marrow Transplant 1998; 22 Suppl 5:S21.</a></li><li><a class="nounderline abstract_t">Laurence V, Pierga JY, Barthier S, et al. Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor. Am J Clin Oncol 2005; 28:301.</a></li><li><a class="nounderline abstract_t">Burdach S, Jürgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11:1482.</a></li><li><a class="nounderline abstract_t">Oberlin O, Rey A, Desfachelles AS, et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. J Clin Oncol 2006; 24:3997.</a></li><li><a class="nounderline abstract_t">Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010; 28:3284.</a></li><li><a class="nounderline abstract_t">Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001; 19:2812.</a></li><li><a class="nounderline abstract_t">Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15:697.</a></li><li><a class="nounderline abstract_t">Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000; 11:1451.</a></li><li><a class="nounderline abstract_t">Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11:1911.</a></li><li><a class="nounderline abstract_t">Hawkins D, Barnett T, Bensinger W, et al. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol 2000; 34:328.</a></li><li><a class="nounderline abstract_t">Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001; 19:870.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li class="breakAll">Children's Oncology Group: Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Viewed May 15, 2019. </li><li><a class="nounderline abstract_t">Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51:163.</a></li><li><a class="nounderline abstract_t">Huang T, Li F, Yan Z, et al. Effectiveness of 18F-FDG PET/CT in the diagnosis, staging and recurrence monitoring of Ewing sarcoma family of tumors: A meta-analysis of 23 studies. Medicine (Baltimore) 2018; 97:e13457.</a></li><li><a class="nounderline abstract_t">Marina NM, Liu Q, Donaldson SS, et al. Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study. Cancer 2017; 123:2551.</a></li><li><a class="nounderline abstract_t">Weston CL, Douglas C, Craft AW, et al. Establishing long-term survival and cure in young patients with Ewing's sarcoma. Br J Cancer 2004; 91:225.</a></li><li><a class="nounderline abstract_t">Bacci G, Balladelli A, Forni C, et al. Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment. Ann Oncol 2007; 18:2037.</a></li><li><a class="nounderline abstract_t">Wasilewski-Masker K, Liu Q, Yasui Y, et al. Late recurrence in pediatric cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101:1709.</a></li><li><a class="nounderline abstract_t">Leavey PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer 2008; 51:334.</a></li><li><a class="nounderline abstract_t">Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011; 57:549.</a></li><li><a class="nounderline abstract_t">Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002; 94:561.</a></li><li><a class="nounderline abstract_t">Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005; 23:4354.</a></li><li><a class="nounderline abstract_t">Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001; 19:3463.</a></li><li><a class="nounderline abstract_t">Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009; 53:1029.</a></li><li><a class="nounderline abstract_t">Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006; 47:795.</a></li><li><a class="nounderline abstract_t">Oesterheld JE, Reed DR, Setty BA, et al. Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. Pediatr Blood Cancer 2020; 67:e28370.</a></li><li><a class="nounderline abstract_t">Fox E, Patel S, Wathen JK, et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist 2012; 17:321.</a></li><li><a class="nounderline abstract_t">Magrath I, Sandlund J, Raynor A, et al. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol 1986; 18 Suppl 2:S25.</a></li><li><a class="nounderline abstract_t">McCabe M, Kirton L, Khan M, et al. Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). J Clin Oncol 2022; 40; 17S.</a></li><li><a class="nounderline abstract_t">McCabe MB, Kirston L, Khan M, et al. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). J Clin Oncol 2020; 38;15S.</a></li><li><a class="nounderline abstract_t">Italiano A, Mir O, Mathoulin-Pelissier S, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2020; 21:446.</a></li><li><a class="nounderline abstract_t">Xue R, Lewis VO, Moon BS, Lin PP. Local recurrence of Ewing sarcoma: Is wide excision an acceptable treatment? J Surg Oncol 2019; 120:746.</a></li><li><a class="nounderline abstract_t">de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000; 18:204.</a></li><li><a class="nounderline abstract_t">Subbiah V, Braña I, Longhi A, et al. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res 2022; 28:2762.</a></li><li><a class="nounderline abstract_t">Kennedy AL, Vallurupalli M, Chen L, et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget 2015; 6:30178.</a></li><li><a class="nounderline abstract_t">Sankar S, Theisen ER, Bearss J, et al. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res 2014; 20:4584.</a></li><li><a class="nounderline abstract_t">Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009; 15:750.</a></li><li><a class="nounderline abstract_t">Fuchs B, Valenzuela RG, Inwards C, et al. Complications in long-term survivors of Ewing sarcoma. Cancer 2003; 98:2687.</a></li><li><a class="nounderline abstract_t">Navid F, Billups C, Liu T, et al. Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer 2008; 44:983.</a></li><li><a class="nounderline abstract_t">Ginsberg JP, Goodman P, Leisenring W, et al. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst 2010; 102:1272.</a></li><li><a class="nounderline abstract_t">Hamilton SN, Carlson R, Hasan H, et al. Long-term Outcomes and Complications in Pediatric Ewing Sarcoma. Am J Clin Oncol 2017; 40:423.</a></li><li><a class="nounderline abstract_t">Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood 2007; 109:46.</a></li><li><a class="nounderline abstract_t">Rodriguez-Galindo C, Poquette CA, Marina NM, et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol 2000; 22:321.</a></li><li><a class="nounderline abstract_t">Caruso J, Shulman DS, DuBois SG. Second malignancies in patients treated for Ewing sarcoma: A systematic review. Pediatr Blood Cancer 2019; 66:e27938.</a></li></ol></div><div id="topicVersionRevision">Topic 7740 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817284" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11251014" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2213103" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17238190" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9747829" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9743460" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ewing's sarcoma treatment in Scandinavia 1984-1990--ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9053479" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9876058" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1995522" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17569105" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20152770" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ewing's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1938559" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2025847" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Radiation therapy as local treatment in Ewing's sarcoma. Results of the Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17219445" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388557" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adult Ewing sarcoma: survival and local control outcomes in 36 patients with metastatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28550026" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9193352" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3189226" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Adults with Ewing's sarcoma. An analysis of 16 patients at the Dana-Farber Cancer Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7360479" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ewing sarcoma: its course and treatment in 50 adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1392154" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : [Ewing's sarcoma of bone in adults: an anatomic-clinical study of 30 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426329" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23840168" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adult ewing sarcoma: survival and local control outcomes in 102 patients with localized disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22959474" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28710342" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10838532" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22752372" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Timing of surgery and the role of adjuvant radiotherapy in ewing sarcoma of the chest wall: a single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26308634" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The Neurological Compromised Spine Due to Ewing Sarcoma. What First: Surgery or Chemotherapy? Therapy, Survival, and Neurological Outcome of 15 Cases With Primary Ewing Sarcoma of the Vertebral Column.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304893" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3334970" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Malignant peripheral neuroectodermal tumors. A retrospective analysis of 42 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10091746" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Extraskeletal Ewing's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9482414" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401006" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Extraosseous localized ewing tumors: improved outcome with anthracyclines--the French society of pediatric oncology and international society of pediatric oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27297500" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36522207" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2099751" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12594313" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30188789" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26579879" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34652968" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23091096" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy: A long-term follow-up report from Children’s Oncology Group study AEWS0031</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10741300" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349548" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452921" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Reconstruction with modular hemipelvic prostheses for periacetabular tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26537339" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Implantation of customized 3-D printed titanium prosthesis in limb salvage surgery: a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32158723" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Three-dimensional-printing Technology in Hip and Pelvic Surgery: Current Landscape.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31381161" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Surgical treatment for pelvic Ewing sarcoma: What is a safe and functional acetabular reconstruction when combined with modern multidisciplinary treatments?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25251206" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10674016" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12504050" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979636" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A systematic review of optimal treatment strategies for localized Ewing's sarcoma of bone after neo-adjuvant chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687792" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10623687" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27216741" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23402991" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Local control and sequelae in localised Ewing tumours of the spine: a French retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28837533" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Ewing Sarcoma of the Spine: Prognostic Variables for Survival and Local Control in Surgically Treated Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19829278" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ewing and osteogenic sarcoma: evidence for multidisciplinary management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33093732" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Spondylectomy for Primary Ewing Lumbar Sarcoma in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26166072" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Systematic Review of En Bloc Resection in the Management of Ewing's Sarcoma of the Mobile Spine with Respect to Local Control and Disease-Free Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22457213" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Results of surgical resection in pelvic Ewing's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22457213" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Results of surgical resection in pelvic Ewing's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7595741" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435062" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment strategies for metastatic Ewing's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3625245" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Metastatic Ewing's sarcoma: remission induction and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8544800" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Outcome in 43 children presenting with metastatic Ewing sarcoma: the St. Jude Children's Research Hospital experience, 1962 to 1992.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9602261" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9376188" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2667789" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10458232" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738574" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2201433" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25917418" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8756388" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15254055" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18802150" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266403" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Surviving childhood cancer; now what? Controversies regarding long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025154" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025149" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508822" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23477833" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22465830" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36669140" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3280743" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7226088" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Radiotherapy and combination chemotherapy in advanced Ewing's Sarcoma-Intergroup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19924786" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26707423" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Management and follow-up of Ewing sarcoma patients with isolated lung metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7646936" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Metachronous pulmonary metastases resection in patients with Ewing's sarcoma initially treated with adjuvant or neoadjuvant chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8235988" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25548538" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Stereotactic body radiotherapy for metastatic and recurrent ewing sarcoma and osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31553693" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34472082" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35427190" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348286" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10490725" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Autologous stem cell transplantation for high-risk pediatric solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9404924" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9989884" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-risk Ewing sarcoma of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15923805" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8101562" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16921053" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the SociétéFrançaise des Cancers de l'Enfant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547982" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11387352" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7670398" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11142486" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8410118" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10797354" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157041" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157041" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157041" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18454470" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30508968" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Effectiveness of 18F-FDG PET/CT in the diagnosis, staging and recurrence monitoring of Ewing sarcoma family of tumors: A meta-analysis of 23 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28222219" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15213720" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Establishing long-term survival and cure in young patients with Ewing's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962210" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19966206" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Late recurrence in pediatric cancer: a report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18506764" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21442722" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Risk of recurrence and survival after relapse in patients with Ewing sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11900241" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781881" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Survival after recurrence of Ewing's sarcoma family of tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11481351" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19637327" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16411206" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32386107" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22363068" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3815717" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32078813" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31286523" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Local recurrence of Ewing sarcoma: Is wide excision an acceptable treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10623711" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35486638" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26337082" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24963049" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19584866" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14669290" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Complications in long-term survivors of Ewing sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18353632" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Second cancers in patients with the Ewing sarcoma family of tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20656964" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25599318" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Long-term Outcomes and Complications in Pediatric Ewing Sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16985182" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10959902" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31347793" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Second malignancies in patients treated for Ewing sarcoma: A systematic review.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
